Comprehensive Treatment of Hematological Patients with SARS-CoV-2 Infection Including Anti-SARS-CoV-2 Monoclonal Antibodies: A Single-Center Experience Case Series

SIMPLE SUMMARY: SARS-CoV-2 causes coronavirus disease (COVID-19) and poses a global health burden. Treatment strategies remain limited and mainly consist of dexamethasone; antiviral agents, such as remdesivir and molnupiravir; and SARS-CoV-2-specific monoclonal antibodies (mABs), including bamlanivimab, casirivimab/imdevimab combination, and, most recently, sotrovimab. SARS-CoV-2 mABs target specific proteins on the viral surface. Patients with hematologic malignancies represent an especially vulnerable cohort. Evidence for the use of SARS-CoV-2 mABs in these patients is scarce, creating an imbalance between urgently needed therapeutic strategies and a lack of randomized controlled trials. In this study, we summarize the characteristics of tolerability and clinical benefits of SARS-CoV-2 mAB application in patients with COVID-19 and hematologic malignancies admitted to our university hospital in Germany. We hope to provide some evidence that may contribute to the management of patients with hematologic malignancies in a world where COVID-19 remains a risk. ABSTRACT: Patients with hematologic malignancies are at high risk of exacerbated condition and higher mortality from coronavirus disease 2019 (COVID-19). Bamlanivimab, casirivimab/imdevimab combination, and sotrovimab are monoclonal antibodies (mABs) that can reduce the risk of COVID-19-related hospitalization. Clinical effectiveness of bamlanivimab and casirivimab/imdevimab combination has been shown for the Delta variant (B.1.617.2), but the effectiveness of the latter treatment against the Omicron variant (B.1.1.529) has been suggested to be reduced. However, the tolerability and clinical usage of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-specific mABs in patients with hematologic malignancies are less specified. We present a retrospective case series analysis of all SARS-CoV-2-infected patients with hematologic malignancies who received SARS-CoV-2-specific mABs at our facility between February and mid-December 2021. A total of 13 COVID-19 patients (pts) with at least one malignant hematologic diagnosis received SARS-CoV-2-specific mABs at our facility, with 3 pts receiving bamlanivimab and 10 pts receiving casirivimab/imdevimab combination. We observed SARS-CoV-2 clearance in five cases. Furthermore, we observed a reduction in the necessity for oxygen supplementation in five cases where the application was administered off-label. To the best of our knowledge, we present the largest collection of anecdotal cases of SARS-CoV-2-specific monoclonal antibody use in patients with hematological malignancies. Potential benefit of mABs may be reduced duration and/or clearance of persistent SARS-CoV-2 infection.